Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KB | Q9UBF8 | 4/20 | 0.39 |
| ▸ | CA1 | P00915 | 12/20 | 0.38 |
| ▸ | CA2 | P00918 | 12/20 | 0.38 |
| ▸ | CA9 | Q16790 | 12/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20528842 | 1.00 | PI4KB (0.39) | PI4KBCA1CA2CA9GAA | |
| SCHEMBL21628157 | 0.92 | PI4KB (0.46) | PI4KBMAPT | |
| SCHEMBL29644514 | 0.92 | PI4KB (0.46) | PI4KBMAPT | |
| SCHEMBL29715019 | 0.87 | PI4KB (0.41) | PI4KBGAARXFP1MAPT | |
| SCHEMBL20528829 | 0.87 | PI4KB (0.41) | PI4KBGAARXFP1MAPT | |
| SCHEMBL20528839 | 0.86 | CRHR1 (0.42) | PI4KBMAPTKDM4ENPC1 | |
| SCHEMBL20529481 | 0.86 | PI4KB (0.54) | PI4KBMAPTKDM4E | |
| SCHEMBL29644488 | 0.86 | PI4KB (0.54) | PI4KBMAPTKDM4E | |
| SCHEMBL23387094 | 0.86 | PI4KB (0.38) | PI4KBRXFP1MAPT | |
| SCHEMBL21628170 | 0.85 | PI4KB (0.40) | PI4KBRXFP1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4676485-A1 | COMPOUND AND FORMULATION FOR SYSTEMIC THERAPY BY ORAL TRANSMUCOSAL ADMINISTRATION | CUROVIR AB (SE) | 2026-01-14 | — | — | EP | claimed |
| WO-2024184442-A1 | COMPOUND AND FORMULATION FOR SYSTEMIC THERAPY BY ORAL TRANSMUCOSAL ADMINISTRATION | CUROVIR AB (SE) | 2024-09-12 | — | — | WO | claimed |
| EP-4028131-A1 | HETEROAROMATIC COMPOUNDS USEFUL IN THERAPY | CUROVIR AB (SE) | 2022-07-20 | — | — | EP | claimed |
| CN-110520424-B | Heteroaromatic compounds for therapy | 库洛维公司 | 2022-06-21 | — | — | CN | claimed |
| EP-4676485-A1 | COMPOUND AND FORMULATION FOR SYSTEMIC THERAPY BY ORAL TRANSMUCOSAL ADMINISTRATION | CUROVIR AB (SE) | 2026-01-14 | — | — | EP | disclosed |
| WO-2024184442-A1 | COMPOUND AND FORMULATION FOR SYSTEMIC THERAPY BY ORAL TRANSMUCOSAL ADMINISTRATION | CUROVIR AB (SE) | 2024-09-12 | — | — | WO | disclosed |